Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments), Technology (IVD Testing, Anatomic pathology, Imaging, Biopsy), Type (Tumors, Breast, Lung Cancer), Application, End User (Hospitals) & Region – Global Forecast to 2031
The cancer diagnostics market is projected to reach USD 44.92 billion by 2031 from USD 29.86 billion in 2026, registering a CAGR of 7.0%.
Cancer diagnostics play a critical role in oncology by enabling early detection, accurate diagnosis, disease characterization, treatment selection, and ongoing monitoring of cancer. The cancer diagnostics market, segmented by product, comprises a broad portfolio of instruments and consumables used across in vitro diagnostics (IVD), anatomic pathology, and imaging-based diagnostics. Market growth is driven by the increasing adoption of advanced diagnostic technologies, sustained demand for consumables, rising global cancer incidence, expanding screening initiatives, and growing diagnostic testing volumes.
The market encompasses a wide range of diagnostic technologies, including PCR, immunohistochemistry (IHC), in situ hybridization (ISH), next-generation sequencing (NGS), microarrays, flow cytometry, immunoassays, histopathology, biopsy, CT, MRI, PET, mammography, and ultrasound. These technologies are used to diagnose both solid tumors and hematological malignancies, supporting applications such as cancer screening, early detection, disease diagnosis and characterization, treatment decision-making, and disease monitoring, including recurrence detection.
Based on product, the cancer diagnostics market is segmented into IVD testing, anatomic pathology, and imaging-based diagnostics. Among these, IVD testing accounted for the largest market share and is projected to witness the fastest growth during the forecast period. The segment's dominance is driven by the increasing global burden of cancer, growing emphasis on early detection and precision oncology, rising adoption of liquid biopsy and molecular diagnostic technologies, and expanding use of biomarker-based testing for cancer screening, diagnosis, treatment selection, and disease monitoring. Continuous advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), immunoassays, companion diagnostics, and AI-enabled diagnostic platforms have significantly enhanced diagnostic accuracy, sensitivity, and turnaround time. Supported by increasing healthcare investments, favorable reimbursement for molecular testing, government-led cancer screening initiatives, and expanding access to personalized medicine, the IVD testing segment is expected to maintain its leading position in the global cancer diagnostics market throughout the forecast period.
Based on end user, the cancer diagnostics market is segmented into hospitals and clinical laboratories. Among these, hospitals account for the largest market share due to their high patient volumes, comprehensive diagnostic infrastructure, and ability to provide integrated cancer care encompassing screening, diagnosis, treatment planning, and disease monitoring under a single setting. Hospitals are the primary centers for advanced imaging, biopsy procedures, molecular testing, and multidisciplinary oncology care, driving significant demand for cancer diagnostic services. The increasing adoption of precision oncology, companion diagnostics, next-generation sequencing (NGS), and AI-enabled diagnostic workflows, coupled with rising investments in hospital-based cancer centers and expanding access to advanced diagnostic technologies, continues to strengthen the dominance of the hospital segment. Furthermore, growing government initiatives for cancer screening, increasing cancer admissions, and the integration of digital pathology and laboratory information systems are reinforcing the leading position of hospitals in the global cancer diagnostics market, while clinical laboratories continue to witness steady growth driven by increasing outsourcing of specialized molecular and genomic testing.
Based on region, the cancer diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest market share in 2025 and continues to serve as the primary market driver, supported by its advanced healthcare infrastructure, high healthcare expenditure, favorable reimbursement policies, and early adoption of innovative cancer diagnostic technologies. The region has a high prevalence of cancer, well-established screening programs, and increasing demand for early detection and precision oncology, resulting in the widespread adoption of molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, companion diagnostics, digital pathology, and advanced imaging technologies across hospitals, cancer centers, and clinical laboratories. The strong presence of leading diagnostics companies, continuous technological advancements, substantial investments in oncology research, supportive regulatory frameworks, and expanding integration of artificial intelligence into cancer diagnostics further reinforce North America's market leadership.
A breakdown of the primary respondents (supply-side) for the cancer diagnostics market referred to in this report is provided below:
Cancer diagnostics play a critical role in oncology by enabling early detection, accurate diagnosis, disease characterization, treatment selection, and ongoing monitoring of cancer. The cancer diagnostics market, segmented by product, comprises a broad portfolio of instruments and consumables used across in vitro diagnostics (IVD), anatomic pathology, and imaging-based diagnostics. Market growth is driven by the increasing adoption of advanced diagnostic technologies, sustained demand for consumables, rising global cancer incidence, expanding screening initiatives, and growing diagnostic testing volumes.
The market encompasses a wide range of diagnostic technologies, including PCR, immunohistochemistry (IHC), in situ hybridization (ISH), next-generation sequencing (NGS), microarrays, flow cytometry, immunoassays, histopathology, biopsy, CT, MRI, PET, mammography, and ultrasound. These technologies are used to diagnose both solid tumors and hematological malignancies, supporting applications such as cancer screening, early detection, disease diagnosis and characterization, treatment decision-making, and disease monitoring, including recurrence detection.
Based on product, the cancer diagnostics market is segmented into IVD testing, anatomic pathology, and imaging-based diagnostics. Among these, IVD testing accounted for the largest market share and is projected to witness the fastest growth during the forecast period. The segment's dominance is driven by the increasing global burden of cancer, growing emphasis on early detection and precision oncology, rising adoption of liquid biopsy and molecular diagnostic technologies, and expanding use of biomarker-based testing for cancer screening, diagnosis, treatment selection, and disease monitoring. Continuous advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), immunoassays, companion diagnostics, and AI-enabled diagnostic platforms have significantly enhanced diagnostic accuracy, sensitivity, and turnaround time. Supported by increasing healthcare investments, favorable reimbursement for molecular testing, government-led cancer screening initiatives, and expanding access to personalized medicine, the IVD testing segment is expected to maintain its leading position in the global cancer diagnostics market throughout the forecast period.
Based on end user, the cancer diagnostics market is segmented into hospitals and clinical laboratories. Among these, hospitals account for the largest market share due to their high patient volumes, comprehensive diagnostic infrastructure, and ability to provide integrated cancer care encompassing screening, diagnosis, treatment planning, and disease monitoring under a single setting. Hospitals are the primary centers for advanced imaging, biopsy procedures, molecular testing, and multidisciplinary oncology care, driving significant demand for cancer diagnostic services. The increasing adoption of precision oncology, companion diagnostics, next-generation sequencing (NGS), and AI-enabled diagnostic workflows, coupled with rising investments in hospital-based cancer centers and expanding access to advanced diagnostic technologies, continues to strengthen the dominance of the hospital segment. Furthermore, growing government initiatives for cancer screening, increasing cancer admissions, and the integration of digital pathology and laboratory information systems are reinforcing the leading position of hospitals in the global cancer diagnostics market, while clinical laboratories continue to witness steady growth driven by increasing outsourcing of specialized molecular and genomic testing.
Based on region, the cancer diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest market share in 2025 and continues to serve as the primary market driver, supported by its advanced healthcare infrastructure, high healthcare expenditure, favorable reimbursement policies, and early adoption of innovative cancer diagnostic technologies. The region has a high prevalence of cancer, well-established screening programs, and increasing demand for early detection and precision oncology, resulting in the widespread adoption of molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, companion diagnostics, digital pathology, and advanced imaging technologies across hospitals, cancer centers, and clinical laboratories. The strong presence of leading diagnostics companies, continuous technological advancements, substantial investments in oncology research, supportive regulatory frameworks, and expanding integration of artificial intelligence into cancer diagnostics further reinforce North America's market leadership.
A breakdown of the primary respondents (supply-side) for the cancer diagnostics market referred to in this report is provided below:
- By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
- By Designation: C-level: 55%, Director Level: 27%, and Others: 18%
- By Region: North America: 43%, Europe: 28%, Asia Pacific: 20%, Latin America: 6% and Middle East & Africa: 3%
Research Coverage
The report evaluates the cancer diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.Reasons to Buy the Report
The report will assist market leaders and new entrants in the cancer diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights into better positioning their businesses and developing effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the cancer diagnostics market.This report provides insights into the following points
- Analysis of Key Drivers (Increasing global burden of cancer driven by aging populations, lifestyle changes, and environmental risk factors; Growing emphasis on early cancer detection and screening to improve patient outcomes and survival rates; Advancements in molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, and companion diagnostics enabling precision oncology; Rising adoption of AI-powered imaging and digital pathology solutions to enhance diagnostic accuracy and workflow efficiency; Increasing investments in cancer research, biomarker discovery, and personalized medicine), restraints (High cost of advanced diagnostic technologies and genomic testing; Limited accessibility to sophisticated diagnostic infrastructure in low- and middle-income countries; Stringent regulatory approval and reimbursement challenges; Complexity in interpreting genomic and molecular data requiring specialized expertise), opportunities (Growing demand for non-invasive diagnostic techniques such as liquid biopsy; Expansion of national cancer screening programs and awareness initiatives; Increasing adoption of precision medicine and companion diagnostics; Rising investments in AI-enabled diagnostics, digital pathology, and multi-cancer early detection (MCED) tests; Growing healthcare infrastructure and diagnostic capabilities in emerging markets), and challenges (Shortage of skilled oncology and pathology professionals; Data privacy, interoperability, and integration issues with digital diagnostic platforms; High validation requirements for novel biomarkers and diagnostic assays; Reimbursement variability across different healthcare systems; Ensuring equitable access to advanced cancer diagnostics while maintaining affordability and diagnostic accuracy).
- Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the cancer diagnostics market.
- Market Development: Thorough knowledge and analysis of the profitable rising markets by product, type, application, technology, end user, and region.
- Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the cancer diagnostics market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the cancer diagnostics market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 CANCER DIAGNOSTICS MARKET OVERVIEW
3.2 ASIA PACIFIC CANCER DIAGNOSTICS MARKET, BY COUNTRY AND TECHNOLOGY
3.3 CANCER DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH (2026?2031)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing incidence of cancer
4.2.1.2 Growth in number of private diagnostics centers
4.2.1.3 Availability of favorable reimbursement policies
4.2.2 RESTRAINTS
4.2.2.1 High capital investment requirements
4.2.2.2 High cost of advanced diagnostic imaging systems
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing adoption of companion diagnostics
4.2.3.2 Expansion of organized cancer screening programs
4.2.3.3 Growing demand for cancer diagnostics in emerging markets
4.2.4 CHALLENGES
4.2.4.1 Increasing adoption of refurbished diagnostic imaging systems
4.2.4.2 Shortage of skilled professionals
4.2.4.3 Limited healthcare infrastructure and low awareness in developing countries
4.2.4.4 Product recalls and diagnostic test failures
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN CANCER DIAGNOSTICS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 INVESTMENT AND FUNDING SCENARIO
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE BY PRODUCT
5.6.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
5.6.3 AVERAGE SELLING PRICE, BY REGION
5.6.3.1 Average selling price of glucose monitoring test strips, by region
5.6.3.2 Average selling price of infectious disease testing products, by region
5.6.3.3 Average selling price of cardiometabolic monitoring products, by region
5.7 VALUE CHAIN ANALYSIS
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 CASE STUDY ANALYSIS
5.9.1 PRICE IMPACT ANALYSIS
5.9.2 IMPACT ON REGION
5.9.2.1 North America
5.9.2.2 Europe
5.9.2.3 Asia Pacific
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 IVD TESTING
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Molecular diagnostics
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Biochemical technologies
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 LIST OF MAJOR PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GENERATIVE AI ON CANCER DIAGNOSTICS MARKET
6.5.1 INTRODUCTION
6.5.2 TOP USE CASES AND MARKET POTENTIAL
6.5.3 KEY COMPANIES IMPLEMENTING AI
6.5.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CANCER DIAGNOSTICS
7.2.1.1 Eco-friendly Initiatives
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS OF VARIOUS END USERS
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 CANCER DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 SCREENING & EARLY DETECTION
9.2.1 INCREASING EMPHASIS ON EARLY CANCER DETECTION TO DRIVE SEGMENT
9.3 DIAGNOSIS & DISEASE CHARACTERIZATION
9.3.1 GOVERNMENT INITIATIVES TO EXPAND HEALTHCARE ACCESS TO DRIVE SEGMENT
9.4 TREATMENT DECISION SUPPORT
9.4.1 RISING DEMAND FOR PRECISION ONCOLOGY TO PROPEL SEGMENT
9.5 TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT
9.5.1 INCREASING DEMAND FOR DETECTION OF DISEASE PROGRESSION SUPPORT SEGMENT GROWTH
9.6 POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION
9.6.1 GROWING EMPHASIS ON POST-TREATMENT MONITORING TO DRIVE SEGMENT
10 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 IVD TESTING
10.2.1 POLYMERASE CHAIN REACTION
10.2.1.1 PCR-based diagnostic tests preferred as they provide simple representations of genomic data
10.2.2 IN SITU HYBRIDIZATION
10.2.2.1 ISH used for identification of specific mRNA species within sample cells
10.2.3 IMMUNOHISTOCHEMISTRY
10.2.3.1 Increasing use of IHC tests for cancer diagnostics to boost market growth
10.2.4 NEXT-GENERATION SEQUENCING
10.2.4.1 NGS dominates IVD testing market
10.2.5 IMMUNOASSAY
10.2.5.1 Immunoassay segment accounted for second-largest share of cancer diagnostics market for IVD testing
10.2.6 MICROARRAY
10.2.6.1 Cost-effectiveness of microarray technology to support market growth
10.2.7 FLOW CYTOMETRY
10.2.7.1 Limited budgets restrain segment growth
10.2.8 OTHER IVD TECHNOLOGIES
10.3 IMAGING TECHNOLOGIES
10.3.1 MAGNETIC RESONANCE IMAGING
10.3.1.1 Technological advancements to boost segment growth
10.3.2 COMPUTED TOMOGRAPHY
10.3.2.1 CT is widely used technique in cancer diagnostics
10.3.3 POSITRON EMISSION TOMOGRAPHY (PET)
10.3.3.1 Widely used nuclear imaging technique in cancer diagnostics
10.3.4 MAMMOGRAPHY
10.3.4.1 Increasing government initiatives for breast cancer screening to drive segment growth
10.3.5 ULTRASOUND
10.3.5.1 Substantial clinical advancements and technical innovations to support market growth
10.4 ANATOMIC PATHOLOGY
10.4.1 INTRODUCTION
10.4.1.1 Histopathology
10.4.1.1.1 Growing demand for high-throughput, error-free staining to drive market
10.4.1.2 Cytopathology
10.4.1.2.1 Rising cervical cancer screening volumes to boost demand for automated cytology systems
10.5 BIOPSIES
11 CANCER DIAGNOSTICS MARKET, BY TYPE
11.1 INTRODUCTION
11.2 SOLID TUMORS
11.3 BREAST CANCER
11.3.1 SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
11.4 LUNG CANCER
11.4.1 LUNG CANCER SEGMENT ACCOUNTED FOR THE SECOND-LARGEST SHARE
11.5 COLORECTAL CANCER
11.5.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO DRIVE MARKET GROWTH
11.6 GASTRIC CANCER
11.6.1 SEGMENT GROWTH SUPPORTED BY INCREASING ADOPTION OF BIOMARKER-BASED TESTING FOR TREATMENT SELECTION
11.7 HEAD & NECK CANCER
11.7.1 SEGMENT TO BE DRIVEN BY INCREASING AGING POPULATION
11.8 PROSTATE CANCER
11.8.1 RISING GLOBAL DISEASE BURDEN AND EVOLVING DIAGNOSTIC LANDSCAPE TO BOOST SEGMENT
11.9 CERVICAL CANCER
11.9.1 INCREASE IN SCREENING, HPV TESTING, AND BIOMARKER ADOPTION TO DRIVE MARKET GROWTH
11.10 MELANOMA
11.10.1 INCREASING INCIDENCE OF MELANOMA TO DRIVE MARKET GROWTH
11.10.2 OTHER SOLID TUMORS
11.11 LIQUID TUMORS
11.12 LEUKEMIA
11.12.1 SEGMENT CONTINUES TO REPRESENT SIGNIFICANT SHARE OF GLOBAL HEMATOLOGIC (LIQUID) CANCER BURDEN
11.13 MYELOMA
11.13.1 RISING CASES, PARTICULARLY ACROSS ASIA AND AFRICA, TO DRIVE MARKET
11.14 LYMPHOMA
11.14.1 INCREASING DISEASE BURDEN TO DRIVE SEGMENT
12 CANCER DIAGNOSTICS MARKET, BY PRODUCT
12.1 INTRODUCTION
12.2 IVD TESTING
12.2.1 KITS & REAGENTS
12.2.1.1 Increasing adoption due to ease of use to boost segment
12.2.2 INSTRUMENTS
12.2.2.1 PCR instruments
12.2.2.1.1 Cost-effectiveness drives growth of segment
12.2.2.2 NGS instruments
12.2.2.2.1 NGS is an emerging technology for cancer diagnostics
12.2.2.3 Microarrays
12.2.2.3.1 Use in determination of primary sites in metastatic carcinomas to boost market
12.2.3 IN SITU HYBRIDIZATION
12.2.3.1 Use for identification of specific mRNA species within sample cells – key driver
12.2.4 IMMUNOHISTOCHEMISTRY
12.2.4.1 Increasing use of IHC tests for cancer diagnostics to boost market growth
12.2.5 IMMUNOASSAY
12.2.5.1 Segment holds second-largest share of cancer diagnostics market for IVD testing
12.2.6 FLOW CYTOMETRY
12.2.6.1 Use across diagnosis, monitoring, and treatment to propel market
12.2.7 OTHER IVD TESTING INSTRUMENTS
12.3 ANATOMIC PATHOLOGY
12.3.1 INTRODUCTION
12.3.2 INSTRUMENTS
12.3.2.1 Slide staining systems
12.3.2.1.1 Increasing focus on automation to drive market
12.3.2.2 Tissue processing systems
12.3.2.2.1 Use in automatic processing of tissue samples to boost market
12.3.2.3 Cell processors
12.3.2.3.1 Used to remove unwanted matter from cytology samples
12.3.2.4 Microtomes
12.3.2.4.1 Segment gaining traction as rising biopsy volumes and automation drive demand
12.3.2.5 Embedding systems
12.3.2.5.1 Automated tissue embedding gains momentum in cancer diagnostics
12.3.2.6 Cover slippers
12.3.2.6.1 Automated cover slippers strengthen workflow efficiency in cancer diagnostics
12.3.2.7 Digital pathology scanners
12.3.2.7.1 Shift toward automated cancer diagnostics to accelerate segment growth
12.3.2.8 Other anatomic pathology instruments
12.3.3 CONSUMABLES
12.3.3.1 Antibodies
12.3.3.1.1 Cancer diagnostic consumables market
12.3.3.2 Kits & Reagents
12.3.3.2.1 Use of kits is increasing among end users owing to their ease of use
12.3.3.3 Probes
12.3.3.3.1 Probes Enable Precise Molecular Detection in Cancer Diagnostics
12.3.3.4 Other consumables
12.4 IMAGING-BASED
12.4.1 INSTRUMENTS
12.4.1.1 CT systems
12.4.1.1.1 Technological advancements to drive growth of segment
12.4.1.2 Ultrasound systems
12.4.1.2.1 Increasing incidence of cancer to drive segment growth
12.4.2 MRI SYSTEMS
12.4.2.1 Rising cancer incidence and growing adoption of MRI drive market growth
12.4.2.2 Mammography systems
12.4.2.2.1 Increasing incidence of breast cancer to drive growth of segment
12.4.2.3 PET-CT
12.4.2.3.1 Technological advancements in nuclear imaging systems to drive segment
12.4.3 CONSUMABLES
12.4.3.1 Contrast agents
12.4.3.1.1 Increasing incidence of cancer to drive segment
12.4.3.2 Radiopharmaceuticals
12.4.3.2.1 Increasing availability of radioisotopes to drive segment
13 CANCER DIAGNOSTICS MARKET, BY END USER
13.1 INTRODUCTION
13.2 HOSPITALS & CLINICS
13.2.1 SEGMENT IS LARGEST END USER OF CANCER DIAGNOSTIC PRODUCTS
13.3 DIAGNOSTIC LABORATORIES
13.3.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
14 CANCER DIAGNOSTICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 Expected to be dominant in North American market
14.2.2 CANADA
14.2.2.1 High cancer burden, aging population, and expanding screening programs to support market growth
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
14.3.2 UK
14.3.2.1 Favorable government initiatives to drive market growth
14.3.3 FRANCE
14.3.3.1 Increasing government funding for cancer diagnosis and prevention to support market growth
14.3.4 ITALY
14.3.4.1 High incidence of cancer to support market growth
14.3.5 SPAIN
14.3.5.1 High incidence of chronic diseases to drive market growth
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Increasing healthcare expenditure to drive market growth
14.4.2 JAPAN
14.4.2.1 Advanced healthcare infrastructure to support market growth
14.4.3 INDIA
14.4.3.1 Expanding healthcare sector in country to drive market growth
14.4.4 SOUTH KOREA
14.4.4.1 Focus on genomic research and precision medicine to boost market growth
14.4.5 AUSTRALIA
14.4.6 REST OF ASIA PACIFIC
14.4.7 LATIN AMERICA
14.4.7.1 Increasing number of cancer screening programs to support market growth
14.4.8 BRAZIL
14.4.8.1 Expansion of cancer screening programs to support market growth
14.4.9 MEXICO
14.4.9.1 Increasing cancer screening initiatives and diagnostic infrastructure to drive market growth
14.4.10 REST OF LATIN AMERICA
14.4.11 MIDDLE EAST & AFRICA
14.4.11.1 Increasing incidence of cancer to drive market growth
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER DIAGNOSTICS MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY VALUATION AND FINANCIAL METRICS
15.6 BRAND/PRODUCT COMPARISON
15.6.1 ABBOTT
15.6.2 F. HOFFMANN-LA ROCHE LTD.
15.6.3 DANAHER
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.7.1 STARS
15.7.2 EMERGING LEADERS
15.7.3 PERVASIVE PLAYERS
15.7.4 PARTICIPANTS
15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025
15.7.5.1 Company footprint
15.7.5.2 Region footprint
15.7.5.3 End user footprint
15.7.5.4 Product footprint
15.7.5.5 Technology footprint
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
15.8.1 PROGRESSIVE COMPANIES
15.8.2 RESPONSIVE COMPANIES
15.8.3 DYNAMIC COMPANIES
15.8.4 STARTING BLOCKS
15.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.9.1 DETAILED LIST OF KEY STARTUPS/SMES
15.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
15.10 COMPETITIVE SCENARIO
15.10.1 PRODUCT LAUNCHES AND APPROVALS
16 COMPAMY PROFILE
16.1 KEY PLAYERS
16.1.1 F. HOFFMANN-LA ROCHE
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches and approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 DANAHER CORPORATION
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches and approvals
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 THERMO FISHER SCIENTIFIC INC
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches and approvals
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 ABBOTT LABORATORIES
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Deals
16.1.4.3.2 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 AGILENT TECHNOLOGIES INC.
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches and approvals
16.1.5.3.2 Deals
16.1.5.3.3 Expansions
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 QIAGEN N.V.
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches and approvals
16.1.6.3.2 Deals
16.1.6.3.3 Expansions
16.1.6.4 MnM view
16.1.6.4.1 Right to win
16.1.6.4.2 Strategic choices
16.1.6.4.3 Weaknesses and competitive threats
16.1.7 ILLUMINA, INC
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches and approvals
16.1.7.3.2 Deals
16.1.7.3.3 Expansions
16.1.7.4 MnM view
16.1.7.4.1 Right to win
16.1.7.4.2 Strategic choices
16.1.7.4.3 Weaknesses and competitive threats
16.1.8 HOLOGIC, INC
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product launches and approvals
16.1.8.3.2 Deals
16.1.8.3.3 Expansions
16.1.8.4 MnM view
16.1.8.4.1 Right to win
16.1.8.4.2 Strategic choices
16.1.8.4.3 Weaknesses and competitive threats
16.1.9 BECTON, DICKINSON AND COMPANY
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches and approvals
16.1.9.3.2 Deals
16.1.9.4 MnM view
16.1.9.4.1 Right to win
16.1.9.4.2 Strategic choices
16.1.9.4.3 Weaknesses and competitive threats
16.1.10 SIEMENS HEALTHINEERS AG
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches and approvals
16.1.10.3.2 Expansions
16.1.10.4 MnM view
16.1.10.4.1 Right to win
16.1.10.4.2 Strategic choices
16.1.10.4.3 Weaknesses and competitive threats
16.1.11 EXACT SCIENCES CORPORATION
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches and approvals
16.1.11.3.2 Deals
16.1.11.3.3 Expansions
16.1.12 GUARDANT HEALTH, INC
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches and approvals
16.1.12.3.2 Deals
16.1.13 SYSMEX CORPORATION
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Expansions
16.1.14 BIOM?RIEUX SA.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches and approvals
16.1.15 MYRIAD GENETICS, INC
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Product launches and approvals
16.1.15.3.2 Deals
16.2 OTHER PLAYERS
16.2.1 NEOGENOMICS, INC
16.2.2 NATERA, INC
16.2.3 TEMPUS AI, INC
16.2.4 GRAIL, INC
16.2.5 CARIS LIFE SCIENCES, INC, INC.
16.2.6 PERSONALIS, INC
16.2.7 DELFI DIAGNOSTICS, INC
16.2.8 FULGENT GENETICS, INC
16.2.9 BURNING ROCK BIOTECH LIMITED
16.2.10 GENETRON HOLDINGS LIMITED
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.2 RESEARCH APPROACH
17.2.1 SECONDARY RESEARCH
17.2.1.1 Key data from secondary sources
17.2.2 PRIMARY DATA
17.2.2.1 Primary sources
17.2.2.2 Key data from primary sources
17.2.2.3 Key industry insights
17.3 MARKET SIZE ESTIMATION
17.3.1 BOTTOM-UP APPROACH
17.3.1.1 Approach 1: Company revenue estimation approach
17.3.1.2 Approach 2: Presentations of companies and primary interviews
17.3.1.3 Growth forecast
17.3.2 TOP-DOWN APPROACH
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 MARKET SHARE ANALYSIS
17.6 RESEARCH ASSUMPTIONS
17.6.1 PARAMETRIC ASSUMPTIONS
17.6.2 GROWTH RATE ASSUMPTIONS
17.7 RESEARCH LIMITATIONS
17.8 RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 CANCER DIAGNOSTICS MARKET OVERVIEW
3.2 ASIA PACIFIC CANCER DIAGNOSTICS MARKET, BY COUNTRY AND TECHNOLOGY
3.3 CANCER DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH (2026?2031)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing incidence of cancer
4.2.1.2 Growth in number of private diagnostics centers
4.2.1.3 Availability of favorable reimbursement policies
4.2.2 RESTRAINTS
4.2.2.1 High capital investment requirements
4.2.2.2 High cost of advanced diagnostic imaging systems
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing adoption of companion diagnostics
4.2.3.2 Expansion of organized cancer screening programs
4.2.3.3 Growing demand for cancer diagnostics in emerging markets
4.2.4 CHALLENGES
4.2.4.1 Increasing adoption of refurbished diagnostic imaging systems
4.2.4.2 Shortage of skilled professionals
4.2.4.3 Limited healthcare infrastructure and low awareness in developing countries
4.2.4.4 Product recalls and diagnostic test failures
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN CANCER DIAGNOSTICS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 INVESTMENT AND FUNDING SCENARIO
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE BY PRODUCT
5.6.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
5.6.3 AVERAGE SELLING PRICE, BY REGION
5.6.3.1 Average selling price of glucose monitoring test strips, by region
5.6.3.2 Average selling price of infectious disease testing products, by region
5.6.3.3 Average selling price of cardiometabolic monitoring products, by region
5.7 VALUE CHAIN ANALYSIS
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 CASE STUDY ANALYSIS
5.9.1 PRICE IMPACT ANALYSIS
5.9.2 IMPACT ON REGION
5.9.2.1 North America
5.9.2.2 Europe
5.9.2.3 Asia Pacific
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 IVD TESTING
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Molecular diagnostics
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Biochemical technologies
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 LIST OF MAJOR PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GENERATIVE AI ON CANCER DIAGNOSTICS MARKET
6.5.1 INTRODUCTION
6.5.2 TOP USE CASES AND MARKET POTENTIAL
6.5.3 KEY COMPANIES IMPLEMENTING AI
6.5.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CANCER DIAGNOSTICS
7.2.1.1 Eco-friendly Initiatives
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS OF VARIOUS END USERS
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 CANCER DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 SCREENING & EARLY DETECTION
9.2.1 INCREASING EMPHASIS ON EARLY CANCER DETECTION TO DRIVE SEGMENT
9.3 DIAGNOSIS & DISEASE CHARACTERIZATION
9.3.1 GOVERNMENT INITIATIVES TO EXPAND HEALTHCARE ACCESS TO DRIVE SEGMENT
9.4 TREATMENT DECISION SUPPORT
9.4.1 RISING DEMAND FOR PRECISION ONCOLOGY TO PROPEL SEGMENT
9.5 TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT
9.5.1 INCREASING DEMAND FOR DETECTION OF DISEASE PROGRESSION SUPPORT SEGMENT GROWTH
9.6 POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION
9.6.1 GROWING EMPHASIS ON POST-TREATMENT MONITORING TO DRIVE SEGMENT
10 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 IVD TESTING
10.2.1 POLYMERASE CHAIN REACTION
10.2.1.1 PCR-based diagnostic tests preferred as they provide simple representations of genomic data
10.2.2 IN SITU HYBRIDIZATION
10.2.2.1 ISH used for identification of specific mRNA species within sample cells
10.2.3 IMMUNOHISTOCHEMISTRY
10.2.3.1 Increasing use of IHC tests for cancer diagnostics to boost market growth
10.2.4 NEXT-GENERATION SEQUENCING
10.2.4.1 NGS dominates IVD testing market
10.2.5 IMMUNOASSAY
10.2.5.1 Immunoassay segment accounted for second-largest share of cancer diagnostics market for IVD testing
10.2.6 MICROARRAY
10.2.6.1 Cost-effectiveness of microarray technology to support market growth
10.2.7 FLOW CYTOMETRY
10.2.7.1 Limited budgets restrain segment growth
10.2.8 OTHER IVD TECHNOLOGIES
10.3 IMAGING TECHNOLOGIES
10.3.1 MAGNETIC RESONANCE IMAGING
10.3.1.1 Technological advancements to boost segment growth
10.3.2 COMPUTED TOMOGRAPHY
10.3.2.1 CT is widely used technique in cancer diagnostics
10.3.3 POSITRON EMISSION TOMOGRAPHY (PET)
10.3.3.1 Widely used nuclear imaging technique in cancer diagnostics
10.3.4 MAMMOGRAPHY
10.3.4.1 Increasing government initiatives for breast cancer screening to drive segment growth
10.3.5 ULTRASOUND
10.3.5.1 Substantial clinical advancements and technical innovations to support market growth
10.4 ANATOMIC PATHOLOGY
10.4.1 INTRODUCTION
10.4.1.1 Histopathology
10.4.1.1.1 Growing demand for high-throughput, error-free staining to drive market
10.4.1.2 Cytopathology
10.4.1.2.1 Rising cervical cancer screening volumes to boost demand for automated cytology systems
10.5 BIOPSIES
11 CANCER DIAGNOSTICS MARKET, BY TYPE
11.1 INTRODUCTION
11.2 SOLID TUMORS
11.3 BREAST CANCER
11.3.1 SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
11.4 LUNG CANCER
11.4.1 LUNG CANCER SEGMENT ACCOUNTED FOR THE SECOND-LARGEST SHARE
11.5 COLORECTAL CANCER
11.5.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO DRIVE MARKET GROWTH
11.6 GASTRIC CANCER
11.6.1 SEGMENT GROWTH SUPPORTED BY INCREASING ADOPTION OF BIOMARKER-BASED TESTING FOR TREATMENT SELECTION
11.7 HEAD & NECK CANCER
11.7.1 SEGMENT TO BE DRIVEN BY INCREASING AGING POPULATION
11.8 PROSTATE CANCER
11.8.1 RISING GLOBAL DISEASE BURDEN AND EVOLVING DIAGNOSTIC LANDSCAPE TO BOOST SEGMENT
11.9 CERVICAL CANCER
11.9.1 INCREASE IN SCREENING, HPV TESTING, AND BIOMARKER ADOPTION TO DRIVE MARKET GROWTH
11.10 MELANOMA
11.10.1 INCREASING INCIDENCE OF MELANOMA TO DRIVE MARKET GROWTH
11.10.2 OTHER SOLID TUMORS
11.11 LIQUID TUMORS
11.12 LEUKEMIA
11.12.1 SEGMENT CONTINUES TO REPRESENT SIGNIFICANT SHARE OF GLOBAL HEMATOLOGIC (LIQUID) CANCER BURDEN
11.13 MYELOMA
11.13.1 RISING CASES, PARTICULARLY ACROSS ASIA AND AFRICA, TO DRIVE MARKET
11.14 LYMPHOMA
11.14.1 INCREASING DISEASE BURDEN TO DRIVE SEGMENT
12 CANCER DIAGNOSTICS MARKET, BY PRODUCT
12.1 INTRODUCTION
12.2 IVD TESTING
12.2.1 KITS & REAGENTS
12.2.1.1 Increasing adoption due to ease of use to boost segment
12.2.2 INSTRUMENTS
12.2.2.1 PCR instruments
12.2.2.1.1 Cost-effectiveness drives growth of segment
12.2.2.2 NGS instruments
12.2.2.2.1 NGS is an emerging technology for cancer diagnostics
12.2.2.3 Microarrays
12.2.2.3.1 Use in determination of primary sites in metastatic carcinomas to boost market
12.2.3 IN SITU HYBRIDIZATION
12.2.3.1 Use for identification of specific mRNA species within sample cells – key driver
12.2.4 IMMUNOHISTOCHEMISTRY
12.2.4.1 Increasing use of IHC tests for cancer diagnostics to boost market growth
12.2.5 IMMUNOASSAY
12.2.5.1 Segment holds second-largest share of cancer diagnostics market for IVD testing
12.2.6 FLOW CYTOMETRY
12.2.6.1 Use across diagnosis, monitoring, and treatment to propel market
12.2.7 OTHER IVD TESTING INSTRUMENTS
12.3 ANATOMIC PATHOLOGY
12.3.1 INTRODUCTION
12.3.2 INSTRUMENTS
12.3.2.1 Slide staining systems
12.3.2.1.1 Increasing focus on automation to drive market
12.3.2.2 Tissue processing systems
12.3.2.2.1 Use in automatic processing of tissue samples to boost market
12.3.2.3 Cell processors
12.3.2.3.1 Used to remove unwanted matter from cytology samples
12.3.2.4 Microtomes
12.3.2.4.1 Segment gaining traction as rising biopsy volumes and automation drive demand
12.3.2.5 Embedding systems
12.3.2.5.1 Automated tissue embedding gains momentum in cancer diagnostics
12.3.2.6 Cover slippers
12.3.2.6.1 Automated cover slippers strengthen workflow efficiency in cancer diagnostics
12.3.2.7 Digital pathology scanners
12.3.2.7.1 Shift toward automated cancer diagnostics to accelerate segment growth
12.3.2.8 Other anatomic pathology instruments
12.3.3 CONSUMABLES
12.3.3.1 Antibodies
12.3.3.1.1 Cancer diagnostic consumables market
12.3.3.2 Kits & Reagents
12.3.3.2.1 Use of kits is increasing among end users owing to their ease of use
12.3.3.3 Probes
12.3.3.3.1 Probes Enable Precise Molecular Detection in Cancer Diagnostics
12.3.3.4 Other consumables
12.4 IMAGING-BASED
12.4.1 INSTRUMENTS
12.4.1.1 CT systems
12.4.1.1.1 Technological advancements to drive growth of segment
12.4.1.2 Ultrasound systems
12.4.1.2.1 Increasing incidence of cancer to drive segment growth
12.4.2 MRI SYSTEMS
12.4.2.1 Rising cancer incidence and growing adoption of MRI drive market growth
12.4.2.2 Mammography systems
12.4.2.2.1 Increasing incidence of breast cancer to drive growth of segment
12.4.2.3 PET-CT
12.4.2.3.1 Technological advancements in nuclear imaging systems to drive segment
12.4.3 CONSUMABLES
12.4.3.1 Contrast agents
12.4.3.1.1 Increasing incidence of cancer to drive segment
12.4.3.2 Radiopharmaceuticals
12.4.3.2.1 Increasing availability of radioisotopes to drive segment
13 CANCER DIAGNOSTICS MARKET, BY END USER
13.1 INTRODUCTION
13.2 HOSPITALS & CLINICS
13.2.1 SEGMENT IS LARGEST END USER OF CANCER DIAGNOSTIC PRODUCTS
13.3 DIAGNOSTIC LABORATORIES
13.3.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
14 CANCER DIAGNOSTICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 Expected to be dominant in North American market
14.2.2 CANADA
14.2.2.1 High cancer burden, aging population, and expanding screening programs to support market growth
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
14.3.2 UK
14.3.2.1 Favorable government initiatives to drive market growth
14.3.3 FRANCE
14.3.3.1 Increasing government funding for cancer diagnosis and prevention to support market growth
14.3.4 ITALY
14.3.4.1 High incidence of cancer to support market growth
14.3.5 SPAIN
14.3.5.1 High incidence of chronic diseases to drive market growth
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Increasing healthcare expenditure to drive market growth
14.4.2 JAPAN
14.4.2.1 Advanced healthcare infrastructure to support market growth
14.4.3 INDIA
14.4.3.1 Expanding healthcare sector in country to drive market growth
14.4.4 SOUTH KOREA
14.4.4.1 Focus on genomic research and precision medicine to boost market growth
14.4.5 AUSTRALIA
14.4.6 REST OF ASIA PACIFIC
14.4.7 LATIN AMERICA
14.4.7.1 Increasing number of cancer screening programs to support market growth
14.4.8 BRAZIL
14.4.8.1 Expansion of cancer screening programs to support market growth
14.4.9 MEXICO
14.4.9.1 Increasing cancer screening initiatives and diagnostic infrastructure to drive market growth
14.4.10 REST OF LATIN AMERICA
14.4.11 MIDDLE EAST & AFRICA
14.4.11.1 Increasing incidence of cancer to drive market growth
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER DIAGNOSTICS MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY VALUATION AND FINANCIAL METRICS
15.6 BRAND/PRODUCT COMPARISON
15.6.1 ABBOTT
15.6.2 F. HOFFMANN-LA ROCHE LTD.
15.6.3 DANAHER
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.7.1 STARS
15.7.2 EMERGING LEADERS
15.7.3 PERVASIVE PLAYERS
15.7.4 PARTICIPANTS
15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025
15.7.5.1 Company footprint
15.7.5.2 Region footprint
15.7.5.3 End user footprint
15.7.5.4 Product footprint
15.7.5.5 Technology footprint
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
15.8.1 PROGRESSIVE COMPANIES
15.8.2 RESPONSIVE COMPANIES
15.8.3 DYNAMIC COMPANIES
15.8.4 STARTING BLOCKS
15.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.9.1 DETAILED LIST OF KEY STARTUPS/SMES
15.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
15.10 COMPETITIVE SCENARIO
15.10.1 PRODUCT LAUNCHES AND APPROVALS
16 COMPAMY PROFILE
16.1 KEY PLAYERS
16.1.1 F. HOFFMANN-LA ROCHE
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches and approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 DANAHER CORPORATION
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches and approvals
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 THERMO FISHER SCIENTIFIC INC
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches and approvals
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 ABBOTT LABORATORIES
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Deals
16.1.4.3.2 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 AGILENT TECHNOLOGIES INC.
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches and approvals
16.1.5.3.2 Deals
16.1.5.3.3 Expansions
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 QIAGEN N.V.
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches and approvals
16.1.6.3.2 Deals
16.1.6.3.3 Expansions
16.1.6.4 MnM view
16.1.6.4.1 Right to win
16.1.6.4.2 Strategic choices
16.1.6.4.3 Weaknesses and competitive threats
16.1.7 ILLUMINA, INC
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches and approvals
16.1.7.3.2 Deals
16.1.7.3.3 Expansions
16.1.7.4 MnM view
16.1.7.4.1 Right to win
16.1.7.4.2 Strategic choices
16.1.7.4.3 Weaknesses and competitive threats
16.1.8 HOLOGIC, INC
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product launches and approvals
16.1.8.3.2 Deals
16.1.8.3.3 Expansions
16.1.8.4 MnM view
16.1.8.4.1 Right to win
16.1.8.4.2 Strategic choices
16.1.8.4.3 Weaknesses and competitive threats
16.1.9 BECTON, DICKINSON AND COMPANY
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches and approvals
16.1.9.3.2 Deals
16.1.9.4 MnM view
16.1.9.4.1 Right to win
16.1.9.4.2 Strategic choices
16.1.9.4.3 Weaknesses and competitive threats
16.1.10 SIEMENS HEALTHINEERS AG
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches and approvals
16.1.10.3.2 Expansions
16.1.10.4 MnM view
16.1.10.4.1 Right to win
16.1.10.4.2 Strategic choices
16.1.10.4.3 Weaknesses and competitive threats
16.1.11 EXACT SCIENCES CORPORATION
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches and approvals
16.1.11.3.2 Deals
16.1.11.3.3 Expansions
16.1.12 GUARDANT HEALTH, INC
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches and approvals
16.1.12.3.2 Deals
16.1.13 SYSMEX CORPORATION
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Expansions
16.1.14 BIOM?RIEUX SA.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches and approvals
16.1.15 MYRIAD GENETICS, INC
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Product launches and approvals
16.1.15.3.2 Deals
16.2 OTHER PLAYERS
16.2.1 NEOGENOMICS, INC
16.2.2 NATERA, INC
16.2.3 TEMPUS AI, INC
16.2.4 GRAIL, INC
16.2.5 CARIS LIFE SCIENCES, INC, INC.
16.2.6 PERSONALIS, INC
16.2.7 DELFI DIAGNOSTICS, INC
16.2.8 FULGENT GENETICS, INC
16.2.9 BURNING ROCK BIOTECH LIMITED
16.2.10 GENETRON HOLDINGS LIMITED
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.2 RESEARCH APPROACH
17.2.1 SECONDARY RESEARCH
17.2.1.1 Key data from secondary sources
17.2.2 PRIMARY DATA
17.2.2.1 Primary sources
17.2.2.2 Key data from primary sources
17.2.2.3 Key industry insights
17.3 MARKET SIZE ESTIMATION
17.3.1 BOTTOM-UP APPROACH
17.3.1.1 Approach 1: Company revenue estimation approach
17.3.1.2 Approach 2: Presentations of companies and primary interviews
17.3.1.3 Growth forecast
17.3.2 TOP-DOWN APPROACH
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 MARKET SHARE ANALYSIS
17.6 RESEARCH ASSUMPTIONS
17.6.1 PARAMETRIC ASSUMPTIONS
17.6.2 GROWTH RATE ASSUMPTIONS
17.7 RESEARCH LIMITATIONS
17.8 RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 PROJECTED INCREASE IN CANCER PATIENTS, BY REGION, 2025 VS. 2035 VS. 2045
TABLE 2 CANCER DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2024–2031
TABLE 4 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 5 EUROPE: MACROECONOMIC INDICATORS
TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 9 CANCER DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10 AVERAGE SELLING PRICE OF CANCER TESTS, BY PRODUCT, 2023–2025
TABLE 11 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2023–2025
TABLE 12 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2023–2025
TABLE 13 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2023–2025
TABLE 14 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2023–2025
TABLE 15 CANCER DIAGNOSTICS MARKET: KEY PATENTS, 2023–2025
TABLE 16 KEY COMPANIES IMPLEMENTING AI IN CANCER DIAGNOSTICS MARKET
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 GLOBAL STANDARDS IN CANCER DIAGNOSTICS MARKET
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
TABLE 24 KEY BUYING CRITERIA, BY TECHNOLOGY
TABLE 25 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 26 CANCER DIAGNOSTICS MARKET: UNMET NEEDS OF VARIOUS END USERS
TABLE 27 CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 28 SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 NORTH AMERICA: SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 EUROPE: SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 ASIA PACIFIC: SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 LATIN AMERICA: SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY APPLICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 NORTH AMERICA :DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 EUROPE: DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 ASIA PACIFIC: DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 LATIN AMERICA: DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 NORTH AMERICA :TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 EUROPE: TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 ASIA PACIFIC :TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 LATIN AMERICA :TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 NORTH AMERICA :TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 EUROPE: TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 ASIA PACIFIC :TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 LATIN AMERICA :TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 NORTH AMERICA :POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 EUROPE: POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 ASIA PACIFIC :POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 LATIN AMERICA :POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031(USD MILLION)
TABLE 54 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 55 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 NORTH AMERICA :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 EUROPE: IVD TESTING: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 ASIA PACIFIC :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 LATIN AMERICA :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 CANCER DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA :PCR: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 EUROPE: PCR: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 ASIA PACIFIC :PCR: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 LATIN AMERICA :PCR: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 CANCER DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 NORTH AMERICA: ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 67 EUROPE: ISH: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 ASIA PACIFIC :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 69 LATIN AMERICA :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 70 CANCER DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 NORTH AMERICA: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 EUROPE: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 LATIN AMERICA: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 CANCER DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 NORTH AMERICA :NGS: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 EUROPE: NGS: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 ASIA PACIFIC: NGS: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 LATIN AMERICA :NGS: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 CANCER DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 EUROPE: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 ASIA PACIFIC: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 LATIN AMERICA: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 CANCER DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 86 NORTH AMERICA: MICROARRAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 EUROPE: MICROARRAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 ASIA PACIFIC: MICROARRAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 LATIN AMERICA : MICROARRAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 CANCER DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 NORTH AMERICA: FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 EUROPE: FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ASIA PACIFIC :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 LATIN AMERICA :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 CANCER DIAGNOSTICS MARKET FOR OTHER IVD TECHNOLOGIES, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 NORTH AMERICA :OTHER IVD TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 EUROPE: OTHER IVD TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 ASIA PACIFIC: OTHER IVD TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 LATIN AMERICA: OTHER IVD TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 101 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 NORTH AMERICA: IMAGING TECHNOLOGIES : CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 EUROPE: IMAGING TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 104 ASIA PACIFIC : IMAGING TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 105 LATIN AMERICA :IMAGING TECHNOLOGIES :CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 CANCER DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 107 NORTH AMERICA :MRI : CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 108 EUROPE: MRI: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 109 ASIA PACIFIC :MRI: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 110 LATIN AMERICA :MRI: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 111 CANCER DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, BY TECHNOLOGY,2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA :CT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: CT: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC :CT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 115 LATIN AMERICA :CT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 116 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING, BY REGION, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 117 NORTH AMERICA : PET: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 118 EUROPE: PET: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 ASIA PACIFIC :PET: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 LATIN AMERICA :PET: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 122 NORTH AMERICA :MAMMOGRAPHY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 EUROPE: MAMMOGRAPHY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 ASIA PACIFIC :MAMMOGRAPHY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 LATIN AMERICA :MAMMOGRAPHY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 NORTH AMERICA :ULTRASOUND: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 EUROPE: ULTRASOUND: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 ASIA PACIFIC :ULTRASOUND: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 LATIN AMERICA :ULTRASOUND: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 132 INSTRUMENTS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133 CANCER DIAGNOSTICS MARKET FOR ANATOMIC PATHOLOGY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA : ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 ASIA PACIFIC :ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 LATIN AMERICA :ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 HISTOPATHOLOGY: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY REGION, 2024–2031(USD MILLION)
TABLE 139 NORTH AMERICA :HISTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 EUROPE: HISTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY,2024–2031 (USD MILLION)
TABLE 141 ASIA PACIFIC :HISTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 142 LATIN AMERICA :HISTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY,2024–2031 (USD MILLION)
TABLE 143 CYTOPATHOLOGY: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY REGION, 2024–2031(USD MILLION)
TABLE 144 NORTH AMERICA :CYTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY,2024–2031 (USD MILLION)
TABLE 145 EUROPE: CYTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC :CYTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 LATIN AMERICA :CYTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 CANCER DIAGNOSTICS MARKET FOR BIOPSIES, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 NORTH AMERICA :BIOPSIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: BIOPSIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 ASIA PACIFIC :BIOPSIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 LATIN AMERICA :BIOPSIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154 CANCER DIAGNOSTICS MARKET FOR SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 NORTH AMERICA :SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 EUROPE: SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 ASIA PACIFIC :SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 LATIN AMERICA :SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 161 BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 162 NORTH AMERICA :BREAST CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 EUROPE: BREAST CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 ASIA PACIFIC :BREAST CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 LATIN AMERICA :BREAST CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 167 LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 NORTH AMERICA :LUNG CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 EUROPE: LUNG CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 ASIA PACIFIC :LUNG CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 LATIN AMERICA :LUNG CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 173 COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 NORTH AMERICA :COLORECTAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 EUROPE: COLORECTAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 ASIA PACIFIC :COLORECTAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 LATIN AMERICA :COLORECTAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 GASTRIC CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 179 GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA :GASTRIC CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: GASTRIC CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC :GASTRIC CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA :GASTRIC CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 HEAD & NECK CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 185 HEAD& NECK CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA :HEAD& NECK CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: HEAD& NECK CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 ASIA PACIFIC :HEAD& NECK CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 LATIN AMERICA :HEAD& NECK CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 191 PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA :PROSTATE CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: PROSTATE CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 ASIA PACIFIC :PROSTATE CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 LATIN AMERICA :PROSTATE CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 CERVICAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 197 CERVICAL CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA :CERVICAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: CERVICAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 ASIA PACIFIC :CERVICAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 LATIN AMERICA :CERVICAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 203 MELANOMA DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA :MELANOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 EUROPE: MELANOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 ASIA PACIFIC :MELANOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 LATIN AMERICA :MELANOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 OTHER SOLID TUMORS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 209 NORTH AMERICA :OTHER SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 EUROPE: OTHER SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 ASIA PACIFIC :OTHER SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 LATIN AMERICA :OTHER SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214 LIQUID TUMORS CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 215 NORTH AMERICA :LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 EUROPE: LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 ASIA PACIFIC :LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 LATIN AMERICA :LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 LEUKEMIA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 220 LEUKEMIA CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 221 NORTH AMERICA :LEUKEMIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 EUROPE: LEUKEMIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 ASIA PACIFIC :LEUKEMIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 LATIN AMERICA :LEUKEMIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 MYELOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 226 MYELOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 227 NORTH AMERICA :MYELOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 EUROPE: MYELOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229 ASIA PACIFIC :MYELOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 LATIN AMERICA :MYELOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 HODGKINS LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 232 LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 233 NORTH AMERICA :LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 EUROPE: LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 ASIA PACIFIC :LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 LATIN AMERICA :LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 238 IVD TESTING: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 239 NORTH AMERICA :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 EUROPE: IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 ASIA PACIFIC :IVD TESTING : CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 LATIN AMERICA :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243 IVD TESTING: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031(USD MILLION)
TABLE 244 KITS & REAGENTS: IVD TESTING CONSUMABLES IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031(USD MILLION)
TABLE 245 NORTH AMERICA: KITS & REAGENTS IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: KITS & REAGENTS IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC : KITS & REAGENTS IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: KITS & REAGENTS IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 INSTRUMENTS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 250 INSTRUMENTS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 251 NORTH AMERICA :IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 EUROPE: IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 ASIA PACIFIC :IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 LATIN AMERICA :IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 PCR INSTRUMENTS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 256 NORTH AMERICA :PCR INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 EUROPE: PCR INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 ASIA PACIFIC :PCR INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 LATIN AMERICA :PCR INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 NGS INSTRUMENTS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 261 NORTH AMERICA :NGS IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 EUROPE: NGS IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 ASIA PACIFIC : NGS IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 LATIN AMERICA: NGS IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 MICROARRAYS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 266 NORTH AMERICA :MICROARRAYS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 EUROPE: MICROARRAYS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 ASIA PACIFIC :MICROARRAYS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 LATIN AMERICA : MICROARRAYS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 IN SITU HYBRIDIZATION: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 271 NORTH AMERICA :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 EUROPE:ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 ASIA PACIFIC :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 LATIN AMERICA :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 IMMUNOHISTOCHEMISTRY: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 276 NORTH AMERICA :IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 EUROPE: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 ASIA PACIFIC :IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 LATIN AMERICA :IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280 IMMUNOASSAY: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 281 NORTH AMERICA :IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 EUROPE: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 ASIA PACIFIC :IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 LATIN AMERICA :IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 FLOW CYTOMETRY: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 286 NORTH AMERICA :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287 EUROPE: FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 ASIA PACIFIC :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 289 LATIN AMERICA :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 291 NORTH AMERICA :OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 EUROPE: OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 ASIA PACIFIC :OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294 LATIN AMERICA :OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 296 AP: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 297 NORTH AMERICA: INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 EUROPE: INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 ASIA PACIFIC :INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 LATIN AMERICA :INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301 INSTRUMENTS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302 SLIDE STAINING SYSTEMS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031(USD MILLION)
TABLE 303 NORTH AMERICA :SLIDE STAINING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 EUROPE: SLIDE STAINING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 ASIA PACIFIC :SLIDE STAINING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 LATIN AMERICA :SLIDE STAINING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 TISSUE PROCESSING SYSTEMS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031(USD MILLION)
TABLE 308 NORTH AMERICA :TISSUE PROCESSING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309 EUROPE: TISSUE PROCESSING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 310 ASIA PACIFIC: TISSUE PROCESSING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 311 LATIN AMERICA :TISSUE PROCESSING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312 CELL PROCESSORS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 313 NORTH AMERICA :CELL PROCESSORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314 EUROPE: CELL PROCESSORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 315 ASIA PACIFIC :CELL PROCESSORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 316 LATIN AMERICA :CELL PROCESSORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 317 MICROTOMES: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 318 NORTH AMERICA :MICROTOMES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 319 EUROPE: MICROTOMES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 1 PROJECTED INCREASE IN CANCER PATIENTS, BY REGION, 2025 VS. 2035 VS. 2045
TABLE 2 CANCER DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2024–2031
TABLE 4 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 5 EUROPE: MACROECONOMIC INDICATORS
TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 9 CANCER DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10 AVERAGE SELLING PRICE OF CANCER TESTS, BY PRODUCT, 2023–2025
TABLE 11 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2023–2025
TABLE 12 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2023–2025
TABLE 13 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2023–2025
TABLE 14 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2023–2025
TABLE 15 CANCER DIAGNOSTICS MARKET: KEY PATENTS, 2023–2025
TABLE 16 KEY COMPANIES IMPLEMENTING AI IN CANCER DIAGNOSTICS MARKET
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 GLOBAL STANDARDS IN CANCER DIAGNOSTICS MARKET
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
TABLE 24 KEY BUYING CRITERIA, BY TECHNOLOGY
TABLE 25 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 26 CANCER DIAGNOSTICS MARKET: UNMET NEEDS OF VARIOUS END USERS
TABLE 27 CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 28 SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29 NORTH AMERICA: SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30 EUROPE: SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 ASIA PACIFIC: SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 LATIN AMERICA: SCREENING & EARLY DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY APPLICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 NORTH AMERICA :DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 EUROPE: DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 ASIA PACIFIC: DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 LATIN AMERICA: DIAGNOSIS & DISEASE CHARACTERIZATION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 NORTH AMERICA :TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 EUROPE: TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 ASIA PACIFIC :TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 LATIN AMERICA :TREATMENT DECISION SUPPORT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 NORTH AMERICA :TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 EUROPE: TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 ASIA PACIFIC :TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 LATIN AMERICA :TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 NORTH AMERICA :POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 EUROPE: POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 ASIA PACIFIC :POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 LATIN AMERICA :POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031(USD MILLION)
TABLE 54 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 55 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 NORTH AMERICA :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 EUROPE: IVD TESTING: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 ASIA PACIFIC :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 LATIN AMERICA :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 CANCER DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA :PCR: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 EUROPE: PCR: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 ASIA PACIFIC :PCR: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 LATIN AMERICA :PCR: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 CANCER DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 NORTH AMERICA: ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 67 EUROPE: ISH: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 ASIA PACIFIC :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 69 LATIN AMERICA :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 70 CANCER DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 NORTH AMERICA: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 EUROPE: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 LATIN AMERICA: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 CANCER DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 NORTH AMERICA :NGS: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 EUROPE: NGS: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 ASIA PACIFIC: NGS: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 LATIN AMERICA :NGS: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 CANCER DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 EUROPE: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 ASIA PACIFIC: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 LATIN AMERICA: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 CANCER DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 86 NORTH AMERICA: MICROARRAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 EUROPE: MICROARRAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 ASIA PACIFIC: MICROARRAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 LATIN AMERICA : MICROARRAY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 CANCER DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 NORTH AMERICA: FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 EUROPE: FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ASIA PACIFIC :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 LATIN AMERICA :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 CANCER DIAGNOSTICS MARKET FOR OTHER IVD TECHNOLOGIES, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 NORTH AMERICA :OTHER IVD TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 EUROPE: OTHER IVD TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 ASIA PACIFIC: OTHER IVD TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 LATIN AMERICA: OTHER IVD TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 101 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 NORTH AMERICA: IMAGING TECHNOLOGIES : CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 EUROPE: IMAGING TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 104 ASIA PACIFIC : IMAGING TECHNOLOGIES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 105 LATIN AMERICA :IMAGING TECHNOLOGIES :CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 CANCER DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 107 NORTH AMERICA :MRI : CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 108 EUROPE: MRI: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 109 ASIA PACIFIC :MRI: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 110 LATIN AMERICA :MRI: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 111 CANCER DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, BY TECHNOLOGY,2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA :CT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: CT: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC :CT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 115 LATIN AMERICA :CT: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 116 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING, BY REGION, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 117 NORTH AMERICA : PET: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 118 EUROPE: PET: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 ASIA PACIFIC :PET: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 LATIN AMERICA :PET: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 122 NORTH AMERICA :MAMMOGRAPHY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 EUROPE: MAMMOGRAPHY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 ASIA PACIFIC :MAMMOGRAPHY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 LATIN AMERICA :MAMMOGRAPHY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 NORTH AMERICA :ULTRASOUND: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 EUROPE: ULTRASOUND: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 ASIA PACIFIC :ULTRASOUND: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 LATIN AMERICA :ULTRASOUND: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 132 INSTRUMENTS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133 CANCER DIAGNOSTICS MARKET FOR ANATOMIC PATHOLOGY, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA : ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 ASIA PACIFIC :ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 LATIN AMERICA :ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 HISTOPATHOLOGY: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY REGION, 2024–2031(USD MILLION)
TABLE 139 NORTH AMERICA :HISTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 EUROPE: HISTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY,2024–2031 (USD MILLION)
TABLE 141 ASIA PACIFIC :HISTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 142 LATIN AMERICA :HISTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY,2024–2031 (USD MILLION)
TABLE 143 CYTOPATHOLOGY: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,BY REGION, 2024–2031(USD MILLION)
TABLE 144 NORTH AMERICA :CYTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY,2024–2031 (USD MILLION)
TABLE 145 EUROPE: CYTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC :CYTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 LATIN AMERICA :CYTOPATHOLOGY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 CANCER DIAGNOSTICS MARKET FOR BIOPSIES, BY TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 149 NORTH AMERICA :BIOPSIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 EUROPE: BIOPSIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 ASIA PACIFIC :BIOPSIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 LATIN AMERICA :BIOPSIES: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154 CANCER DIAGNOSTICS MARKET FOR SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 155 NORTH AMERICA :SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 EUROPE: SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 ASIA PACIFIC :SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 LATIN AMERICA :SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 161 BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 162 NORTH AMERICA :BREAST CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 EUROPE: BREAST CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 ASIA PACIFIC :BREAST CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 LATIN AMERICA :BREAST CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 167 LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 NORTH AMERICA :LUNG CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 EUROPE: LUNG CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 ASIA PACIFIC :LUNG CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 LATIN AMERICA :LUNG CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 173 COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 NORTH AMERICA :COLORECTAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 EUROPE: COLORECTAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 ASIA PACIFIC :COLORECTAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 LATIN AMERICA :COLORECTAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 GASTRIC CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 179 GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA :GASTRIC CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: GASTRIC CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC :GASTRIC CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA :GASTRIC CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 HEAD & NECK CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 185 HEAD& NECK CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA :HEAD& NECK CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: HEAD& NECK CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 ASIA PACIFIC :HEAD& NECK CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 LATIN AMERICA :HEAD& NECK CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 191 PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA :PROSTATE CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: PROSTATE CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 ASIA PACIFIC :PROSTATE CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 LATIN AMERICA :PROSTATE CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 CERVICAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 197 CERVICAL CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA :CERVICAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: CERVICAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 ASIA PACIFIC :CERVICAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 LATIN AMERICA :CERVICAL CANCER: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 203 MELANOMA DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA :MELANOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 EUROPE: MELANOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 ASIA PACIFIC :MELANOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 LATIN AMERICA :MELANOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 OTHER SOLID TUMORS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 209 NORTH AMERICA :OTHER SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 EUROPE: OTHER SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 ASIA PACIFIC :OTHER SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 LATIN AMERICA :OTHER SOLID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214 LIQUID TUMORS CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 215 NORTH AMERICA :LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 EUROPE: LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 ASIA PACIFIC :LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 LATIN AMERICA :LIQUID TUMORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 LEUKEMIA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 220 LEUKEMIA CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 221 NORTH AMERICA :LEUKEMIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 EUROPE: LEUKEMIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 ASIA PACIFIC :LEUKEMIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 LATIN AMERICA :LEUKEMIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 MYELOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 226 MYELOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 227 NORTH AMERICA :MYELOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 EUROPE: MYELOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229 ASIA PACIFIC :MYELOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 LATIN AMERICA :MYELOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 HODGKINS LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 232 LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 233 NORTH AMERICA :LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 EUROPE: LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 ASIA PACIFIC :LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 LATIN AMERICA :LYMPHOMA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 238 IVD TESTING: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 239 NORTH AMERICA :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 EUROPE: IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 ASIA PACIFIC :IVD TESTING : CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 LATIN AMERICA :IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243 IVD TESTING: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031(USD MILLION)
TABLE 244 KITS & REAGENTS: IVD TESTING CONSUMABLES IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031(USD MILLION)
TABLE 245 NORTH AMERICA: KITS & REAGENTS IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: KITS & REAGENTS IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC : KITS & REAGENTS IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: KITS & REAGENTS IVD TESTING: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 INSTRUMENTS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 250 INSTRUMENTS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 251 NORTH AMERICA :IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 EUROPE: IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 ASIA PACIFIC :IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 LATIN AMERICA :IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 PCR INSTRUMENTS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 256 NORTH AMERICA :PCR INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 EUROPE: PCR INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 ASIA PACIFIC :PCR INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 LATIN AMERICA :PCR INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 NGS INSTRUMENTS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 261 NORTH AMERICA :NGS IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 EUROPE: NGS IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 ASIA PACIFIC : NGS IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 LATIN AMERICA: NGS IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 MICROARRAYS: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 266 NORTH AMERICA :MICROARRAYS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 EUROPE: MICROARRAYS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 ASIA PACIFIC :MICROARRAYS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 LATIN AMERICA : MICROARRAYS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 IN SITU HYBRIDIZATION: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 271 NORTH AMERICA :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 EUROPE:ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 ASIA PACIFIC :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 LATIN AMERICA :ISH: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 IMMUNOHISTOCHEMISTRY: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 276 NORTH AMERICA :IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 EUROPE: IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 ASIA PACIFIC :IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 LATIN AMERICA :IMMUNOHISTOCHEMISTRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280 IMMUNOASSAY: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 281 NORTH AMERICA :IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 EUROPE: IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 ASIA PACIFIC :IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284 LATIN AMERICA :IMMUNOASSAY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 FLOW CYTOMETRY: IVD TESTING IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 286 NORTH AMERICA :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287 EUROPE: FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 ASIA PACIFIC :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 289 LATIN AMERICA :FLOW CYTOMETRY: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 291 NORTH AMERICA :OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 EUROPE: OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 ASIA PACIFIC :OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294 LATIN AMERICA :OTHER IVD TESTING INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 ANATOMIC PATHOLOGY: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 296 AP: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 297 NORTH AMERICA: INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 EUROPE: INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 ASIA PACIFIC :INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 LATIN AMERICA :INSTRUMENTS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301 INSTRUMENTS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302 SLIDE STAINING SYSTEMS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031(USD MILLION)
TABLE 303 NORTH AMERICA :SLIDE STAINING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 EUROPE: SLIDE STAINING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305 ASIA PACIFIC :SLIDE STAINING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 LATIN AMERICA :SLIDE STAINING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 TISSUE PROCESSING SYSTEMS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031(USD MILLION)
TABLE 308 NORTH AMERICA :TISSUE PROCESSING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309 EUROPE: TISSUE PROCESSING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 310 ASIA PACIFIC: TISSUE PROCESSING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 311 LATIN AMERICA :TISSUE PROCESSING SYSTEMS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312 CELL PROCESSORS: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 313 NORTH AMERICA :CELL PROCESSORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314 EUROPE: CELL PROCESSORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 315 ASIA PACIFIC :CELL PROCESSORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 316 LATIN AMERICA :CELL PROCESSORS: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 317 MICROTOMES: ANATOMIC PATHOLOGY IN CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 318 NORTH AMERICA :MICROTOMES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 319 EUROPE: MICROTOMES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
The report “Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), by Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020”, analyzes and studies the major market drivers, restraints, and opportunities.
This market is expected to reach $13.1 Billion by 2020 from $7.1 Billion in 2015, and is poised to grow at a CAGR of 12.9% during the forecast period.
The global cancer diagnostics market is segmented on the basis of technology, application, and region.
Major players in the global Cancer Diagnostics System Market are
- Agilent Technologies, Inc. (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- Becton, Dickinson and Company (U.S.)
- Abbott Laboratories, Inc. (U.S.)
- C.R. Bard, Inc. (U.S.)
Based on technology, the cancer diagnostics market is categorized into platform-based and instrument-based. The instrument-based segment is expected to account for a major share of the cancer diagnostics market, by product, in 2015.
Based on the application, the cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, and others. Breast cancer application is expected to account for a major share of the cancer diagnostics market, by application in 2015.
On the basis of region, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises Latin America, Pacific countries, and Middle East and Africa. North America is expected to account for the largest share in the cancer diagnostics market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the cancer diagnostics market.
The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market. However, shortage of trained and skilled personnel poses as a restraint to the market growth of cancer diagnostics. Rise in aging population and increasing cancer cases are likely to create huge opportunity for cancer diagnostics.
More Publications
Transplant Diagnostics Market by Product & Service (Instrument, Software), Technology (PCR, NGS), Application [Diagnostic (Infectious Disease, HLA) Research], Type [Solid Organ (Heart), Bone Marrow], End User (Hospital) & Region -Global Forecast to 2031
US$ 2,970.00
June 2026
484 pages
German Cancer Diagnostics Market Outlook: Innovations, Trends and Opportunities for Suppliers
US$ 4,880.00
May 2013
585 pages
